Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
About this trial
This is an interventional treatment trial for Attention Deficit Hyperactivity Disorder focused on measuring Brain-Computer Interface
Eligibility Criteria
Inclusion Criteria:
- DSM-IV-TR criteria for ADHD, either the combined or inattentive subtype, based on the Diagnostic Interview Schedule for Children (CDISC; Schaffer et al., 2000)
Exclusion Criteria:
- Present or history of medical treatment with stimulant medication and Atomoxetine
- Co-morbid severe psychiatric condition or known sensori-neural deficit e.g. complete blindness or deafness (such that they cannot play computer games)
- History of epileptic seizures
- Known Developmental Delay (i.e. IQ 70 and below)
- Predominantly Hyperactive/impulsive subtype of ADHD (i.e. no predominant inattentive symptoms)
- Present/history polyunsaturated fatty acids supplement intake (e.g. Omega-3 oil, flax seed oil, cod liver oil) in the past 3 months
- Present/history of traditional Chinese medicine (TCM) prescribed for treatment of attention problems in the past 1 month
Sites / Locations
- Child Guidance Clinic, Institute of Mental Health
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Other
Experimental
BCI treatment
Wait-list control
BCI pilot arm
BCI treatment will commence during the week of the Baseline.
BCI treatment will commence 8 weeks after Baseline
This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.